Pharmacokinetics of glycosylated recombinant human granulocyte colony‐stimulating factor (lenograstim) in healthy male volunteers
Authors:
- StevensSTStevens
- V CourVCV Cour
- 1 March 1999
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (3) , 279-284
Abstract
Aims The aim of this open, randomised, crossover, parallel‐group study was to compare the pharmacokinetics and neutrophil responses of lenograstim when administered subcutaneously (s.c.) and intravenously (i.v.). Methods A total of 27 healthy male volunteers was recruited. Lenograstim doses (0.5, 2, 5, or 10 μg kg−1 ) were administered s.c. or i.v. once‐daily for 5 days, and then, after a 10‐day washout period, vice versa for a further 5 days. Lenograstim concentrations and absolute neutrophil counts (ANCs) were measured predosing and postdosing on days 1 and 5. Results Maximum serum concentrations of lenograstim were higher following i.v. dosing (mean 5.2–185.5 vs 0.7–30.0 ng ml−1 after s.c. dosing on day 1) and attained sooner (median 0.5–0.8 vs 4.7–8.7 h on day 1). However, apparent elimination half‐lives of lenograstim were longer following s.c. dosing (mean 2.3–3.3 vs 0.8–1.2 h after i.v. dosing on days 1 and 5). ANCs increased in a dose‐dependent manner with both routes of lenograstim, but more prolonged rises and higher ANC peaks were attained following s.c. doses. ANCs peaked on day 6 following 5 μg kg−1 s.c. doses (mean peak=26.3×109 cells l−1 ), but on day 2 after 5 μg kg−1 i.v. doses (mean peak=12.4×109 cells l−1 ). Irrespective of route, the most common adverse events were headaches and back/spine pain; at doses of up to 5 μg kg−1 these were mild and generally well tolerated. Conclusions While supporting the use of both s.c. and i.v. administered lenograstim to treat neutropenia, these results demonstrate that neutrophil responses are more sustained and prolonged with the s.c. route.Keywords
This publication has 16 references indexed in Scilit:
- Mobilization of CD34+ cells by glycosylated and nonglycosylated G‐CSF in healthy volunteers — a comparative studyEuropean Journal of Haematology, 1997
- LenograstimDrugs, 1995
- Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantationBlood, 1995
- FilgrastimDrugs, 1994
- In Vitro Comparison of the Biological Potency of Glycosylated versus Nonglycosylated rG-CSFClinical Drug Investigation, 1994
- Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropeniaThe Journal of Pediatrics, 1993
- Granulocyte and granulocyte-macrophage colony-stimulating factorsThe Lancet, 1993
- Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF)Drugs, 1991
- THE IMPACT OF COLONY STIMULATING FACTORS ON CANCER CHEMOTHERAPYBritish Journal of Haematology, 1990
- EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPYThe Lancet, 1988